ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients

This study has been completed.

Sponsors and Collaborators: Department of Veterans Affairs
SmithKline Beecham
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00018759
  Purpose

This study aims to determine if treatment with an SSRI antidepressant medication, paroxetine, is associated with cellular calcium response to serotonin, platelet serotonin receptors, and improvement in mood in depressed patients with or without hypertension. It is hypothesized that platelets of hypertensive patients with depressive symptomatology with be hyper-responsive to serotonin. Additionally, treatment with an SSRI antidepressant is expected to produce a down-regulation of the serotonin receptor with an associated reduction in platelet cytosolic calcium response as well as improved mood.


Condition Intervention Phase
Depression
Hypertension
Drug: paroxetine
Behavioral: ongoing psychological screening
Phase IV

MedlinePlus related topics:   Antidepressants    Depression    High Blood Pressure   

Drug Information available for:   Paroxetine    Paroxetine hydrochloride    Paroxetine Mesylate    Calcium gluconate    Serotonin   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Parallel Assignment, Pharmacodynamics Study
Official Title:   Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients

Further study details as provided by Department of Veterans Affairs:

Study Start Date:   March 2001
Estimated Study Completion Date:   October 2003

  Eligibility
Ages Eligible for Study:   25 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Criteria

Subjects for all study groups will be male and between the ages of 25 and 65

Hypertension & Depression Group: Hypertension controlled with an ACE-inhibitor anti-hypertensive; no co-morbid medical conditions known to influence psychological functioning or platelet calcium responses including uncontrolled diabetes, MI or CVA within 6 months of enrollment, secondary hypertension; depression as diagnosed by structured interview and HDRS score of 18; no active participation in another clinical trial; no current suicidal/ homicidal ideation

Hypertension Group: Hypertension controlled with an ACE-inhibitor anti-hypertensive; no co-morbid medical conditions known to influence psychological functioning or platelet calcium responses including uncontrolled diabetes, MI or CVA within 6 months of enrollment, secondary hypertension; no active participation in another clinical trial; no current suicidal/ homicidal ideation

Depression Group: No co-morbid medical conditions known to influence psychological functioning or platelet calcium responses including uncontrolled diabetes, MI or CVA within 6 months of enrollment, secondary hypertension; depression as diagnosed by structured interview and HDRS score of 18; no active participation in another clinical trial; no current suicidal/ homicidal ideation

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018759

Locations
United States, Illinois
Edward Hines Jr. Hospital    
      Hines, Illinois, United States, 60141

Sponsors and Collaborators
Department of Veterans Affairs
SmithKline Beecham
  More Information


Study ID Numbers:   MHBS-023-00S
First Received:   July 3, 2001
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00018759
Health Authority:   United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Serotonin, Hypertension, Depression  

Study placed in the following topic categories:
Depression
Mental Disorders
Vascular Diseases
Mood Disorders
Depressive Disorder
Paroxetine
Serotonin
Behavioral Symptoms
Hypertension

Additional relevant MeSH terms:
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Uptake Inhibitors
Pharmacologic Actions
Serotonin Agents
Therapeutic Uses
Cardiovascular Diseases
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on October 31, 2008




Links to all studies - primarily for crawlers